Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AVATROMBOPAG for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where AVATROMBOPAG was used for Neoplasm malignant.

Most Reported Side Effects for AVATROMBOPAG

Side Effect Reports % Deaths Hosp.
Platelet count decreased 268 14.8% 3 61
Drug ineffective 245 13.5% 4 26
Headache 187 10.3% 4 21
Platelet count increased 167 9.2% 1 21
Fatigue 131 7.2% 4 17
Off label use 111 6.1% 12 16
Platelet count abnormal 90 5.0% 0 16
Nausea 81 4.5% 1 14
Inappropriate schedule of product administration 76 4.2% 2 12
Product dose omission issue 75 4.1% 2 15
Death 68 3.8% 68 5
Arthralgia 57 3.1% 3 7
Dizziness 48 2.7% 1 1
Asthenia 47 2.6% 7 16
Rash 44 2.4% 0 8

Other Indications for AVATROMBOPAG

Immune thrombocytopenia (951) Thrombocytopenia (340) Product used for unknown indication (301) Liver disorder (39) Platelet count decreased (32) Hepatic cirrhosis (28) Immune thrombocytopenic purpura (28) Aplastic anaemia (22) Thrombocytopenic purpura (13) Cirrhosis alcoholic (8)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

AVATROMBOPAG Full Profile All Neoplasm malignant Drugs AVATROMBOPAG Demographics AVATROMBOPAG Timeline